Journal Article

Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment

Suarez-Pinilla, Paula, Ortiz-Garcia de la Foz, Victor, Crespo-Facorro, Benedicto, Juncal-Ruiz, Maria, Neergaard, Karl David, Ramirez-Bonilla, Mariluz, Gomez-Arnau, Jorge, Martinez-Garcia, Obdulia, Tabares-Seisdedos, Rafael

2017

Overview

Introduction Acute akathisia is a neuropsychiatric syndrome with a negative effect on illness outcome. Its incidence in patients treated with antipsychotics has shown to be highly variable across studies. Objectives Our goals were to investigate prevalence, risk factors for the development of acute akathisia, and differences in incidence between antipsychotics in a sample of 493 first episode non-affective psychosis patients. Methods This is a pooled analysis of three prospective, randomized, flexible-dose, and open-label clinical trials. Patients were randomized assigned to different arms of treatment (haloperidol, quetiapine, olanzapine, ziprasidone, risperidone, or aripiprazole). Akathisia was determined using the Barnes Akathisia Scale at 6 weeks after antipsychotic initialization. Univariate analyses were performed to identify demographic, biochemical, substance use, clinical, and treatment-related predictors of acute akathisia. Considering these results, a predictive model based of a subsample of 132 patients was constructed with akathisia as the dependent variable. Results The overall incidence of akathisia was 19.5%. No differences in demographic, biochemical, substance use, and clinical variables were found. Significant incidence differences between antipsychotics were observed ( Χ 2  = 68.21, p  = 0.000): haloperidol (57%), risperidone (20%), aripiprazole (18.2%), ziprasidone (17.2%), olanzapine (3.6%), and quetiapine (3.5%). The predictive model showed that the type of antipsychotic (OR = 21.3, p  = 0.000), need for hospitalization (OR = 2.6, p  = 0.05), and BPRS total score at baseline (OR = 1.05, p  = 0.03) may help to predict akathisia emergence. Conclusions Among second generation antipsychotics, only olanzapine and quetiapine should be considered as akathisia-sparing drugs. The type of antipsychotic, having been hospitalized, and a more severe symptomatology at intake seem to predict the development of acute akathisia.

• Publisher: Springer Berlin Heidelberg,Springer,Springer Nature B.V
• Subject: Adult / Akathisia, Drug-Induced - epidemiology / Antipsychotic agents / Antipsychotic Agents - adverse effects / Antipsychotic Agents - therapeutic use / Antipsychotics / Aripiprazole / Aripiprazole - adverse effects / Aripiprazole - therapeutic use / Benzodiazepines - adverse effects / Benzodiazepines - therapeutic use / Biomedical and Life Sciences / Biomedicine / Clinical trials / Complications and side effects / Distribution / Dosage and administration / Drug therapy / Drug use / Female / Haloperidol / Haloperidol - adverse effects / Haloperidol - therapeutic use / Humans / Incidence / Male / Neuropsychology / Neurosciences / Olanzapine / Original Investigation / Pharmacology/Toxicology / Piperazines - adverse effects / Piperazines - therapeutic use / Prospective Studies / Psychiatry / Psychosis / Psychotic disorders / Psychotic Disorders - drug therapy / Psychotropic drugs / Quetiapine / Quetiapine Fumarate - adverse effects / Quetiapine Fumarate - therapeutic use / Restless legs syndrome / Risk Factors / Risperidone / Risperidone - adverse effects / Risperidone - therapeutic use / Schizophrenia - drug therapy / Side effects / Substance use / Thiazoles - adverse effects / Thiazoles - therapeutic use / Young Adult / Ziprasidone